Interstitial cystitis (IC) is a highly prevalent debilitating disease, with its cardinal symptoms being severe pain, urinary urgency and frequency. The associated pain may eventually lead as a last resort to removal of the bladder. Though the initial trigger for IC remains largely unknown, we propose novel iron chelators as a possible new treatment for this disease. Iron is a mandatory component for the generation of reactive oxygen species (ROS). A substantial decrease in ROS production and thus inflammation can be achieved by effectively sequestering host iron, which we believe may improve outcome and quality of life in IC patients. Novel iron chelators could be used via the intravesical route to reduce or attenuate inflammation by effectively sequestering host iron, thus preventing the production of ROS via the Fenton and Haber-Weiss reactions.

Keywords:
Interstitial cystitis, Iron, Reactive oxygen species, Iron chelation
1.
Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, et al: Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol 2011; 186: 540–544.
2.
Payne CK, Joyce GF, Wise M, Clemens JQ; Urologic Diseases in America Project: Interstitial cystitis and painful bladder syndrome. J Urol 2007; 177: 2042–2049.
3.
Rajasekaran M, Stein P, Parsons CL: Toxic factors in human urine that injure urothelium. Int J Urol 2006; 13: 409–414.
4.
Slobodov G, Feloney M, Gran C, Kyker KD, Hurst RE, Culkin DJ: Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis. J Urol 2004; 171: 1554–1558.
5.
Cvach K, Rosamilia A: Review of intravesical therapies for bladder pain syndrome/interstitial cystitis. Transl Androl Urol 2015; 4: 629–637.
6.
Allègre C, Manhès G, Lewin E: Chemical composition of the earth and the volatility control on\rplanetary genetics. Earth Planet Sci Lett 2001; 185: 49–69.
7.
Dev S, Babitt JL: Overview of iron metabolism in health and disease. Hemodial Int 2017; 21:S6–S20.
8.
Ganz T, Nemeth E: Iron homeostasis in host defence and inflammation. Nat Rev Immunol 2015; 15: 500–510.
9.
Evstatiev R, Gasche C: Iron sensing and signalling. Gut 2012; 61: 933–952.
10.
Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783–788.
11.
Wrighting DM, Andrews NC: Interleukin-6 induces hepcidin expression through STAT3. Blood 2006; 108: 3204–3209.
12.
Ganz T, Nemeth E: Iron sequestration and anemia of inflammation. Semin Hematol 2009; 46: 387–393.
13.
Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271–1276.
14.
Kim A, Fung E, Parikh SG, Valore EV, Gabayan V, Nemeth E, et al: A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin 2014; 123: 1129–1136.
15.
Fubini B, Hubbard A: Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic Biol Med 2003; 34: 1507–1516.
16.
Aisen P, Enns C, Wessling-Resnick M: Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 2001; 33: 940–959.
17.
Finkel T: Signal transduction by reactive oxygen species. J Cell Biol 2011; 194: 7–15.
18.
Lushchak VI: Free radicals, reactive oxygen species, oxidative stress and its classification. Chem Biol Interact 2014; 224: 164–175.
19.
Rani V, Deep G, Singh RK, Palle K, Yadav UC: Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. Life Sci 2016; 148: 183–193.
20.
Iborra M, Moret I, Rausell F, Busó E, Cerrillo E, Sáez-González E, et al: Different genetic expression profiles of oxidative stress and apoptosis-related genes in Crohn’s disease. Digestion 2018; 1–10.
21.
Grek CL, Tew KD: Redox metabolism and malignancy. Curr Opin Pharmacol 2010; 10: 362–368.
22.
Liochev SI, Fridovich I: The haber-weiss cycle – 70 years later: an alternative view. Redox Rep 2002; 7: 55–57.
23.
Ener K, Keske M, Aldemir M, Özcan MF, Okulu E, Özayar A, et al: Evaluation of oxidative stress status and antioxidant capacity in patients with painful bladder syndrome/interstitial cystitis: preliminary results of a randomised study. Int Urol Nephrol 2015; 47: 1297–1302.
24.
Bae WJ, Ha US, Kim S, Kim SJ, Hong SH, Lee JY, et al: Reduction of oxidative stress may play a role in the anti-inflammatory effect of the novel herbal formulation in a rat model of hydrochloric acid-induced cystitis. Neurourol Urodyn 2015; 34: 86–91.
25.
He YQ, Zhang WT, Shi CH, Wang FM, Tian XJ, Ma LL: Phloroglucinol protects the urinary bladder via inhibition of oxidative stress and inflammation in a rat model of cyclophosphamide-induced interstitial cystitis. Chin Med J (Engl) 2015; 128: 956–962.
26.
Xiong S, She H, Sung CK, Tsukamoto H: Iron-dependent activation of NF-kappaB in Kupffer cells: a priming mechanism for alcoholic liver disease. Alcohol 2003; 30: 107–113.
27.
Schreck R, Rieber P, Baeuerle PA: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. Embo 1991; 10: 2247–2258.
28.
Schaeffer EM: Re: intracellular Uropathogenic E. coli exploits host rab35 for iron acquisition and survival within urinary bladder cells. J Urol 2016; 196: 1141–1142.
29.
Kortekaas J, Müller SA, Ringler P, Gregorini M, Weynants VE, Rutten L, et al: Immunogenicity and structural characterisation of an in vitro folded meningococcal siderophore receptor (FrpB, FetA). Microbes Infect 2006; 8: 2145–2153.
30.
Kim DH: Bacterial siderophores promote animal host iron acquisition and growth. Cell 2018; 175: 311–312.
31.
Richardson DR, Ponka P: Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am J Hematol 1998; 58: 299–305.
32.
Muller G, Raymond KN: Specificity and mechanism of ferrioxamine-mediated iron transport in Streptomyces pilosus. J Bacteriol 1984; 160: 304–312.
33.
Jacobs A, Ting WC: Iron chelation with oral desferrioxamine. Lancet 1980; 2: 794.
34.
Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C: Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 1979; 42: 547–555.
35.
Nurchi VM, Crisponi G, Lachowicz JI, Medici S, Peana M, Zoroddu MA: Chemical features of in use and in progress chelators for iron overload. J Trace Elem Med Biol 2016; 38: 10–18.
36.
Coad J, Pedley K: Iron deficiency and iron deficiency anemia in women. Scand J Clin Lab Invest Suppl 2014; 244: 82–89.
37.
Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al: Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370: 1198–1208.
38.
Cox A, Golda N, Nadeau G, Curtis Nickel J, Carr L, Corcos J, Teichman J: CUA guideline: diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Can Urol Assoc J 2016; 10:E136–E155.
39.
Singh PK, Parsek MR, Greenberg EP, Welsh MJ: A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417: 552–555.
40.
GuhaSarkar S, Banerjee R: Intravesical drug delivery: challenges, current status, opportunities and novel strategies. J Control Release 2010; 148: 147–159.
41.
Ishizaka N, Saito K, Mori I, Matsuzaki G, Ohno M, Nagai R: Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats. Arterioscler Thromb Vasc Biol 2005; 25: 2282–2288.
42.
Minaiyan M, Mostaghel E, Mahzouni P: Preventive therapy of experimental colitis with selected iron chelators and anti-oxidants. Int J Prev Med 2012; 3(suppl 1):S162–S169.
43.
Arora N, Caldwell A, Wafa K, Szczesniak A, Caldwell M, Al-Banna N, et al: DIBI, a polymeric hydroxypyridinone iron chelator, reduces ocular inflammation in local and systemic endotoxin-induced uveitis. Clin Hemorheol Microcirc 2018; 69: 153–164.
44.
Islam S, Jarosch S, Zhou J, Parquet Mdel C, Toguri JT, Colp P, et al: Anti-inflammatory and anti-bacterial effects of iron chelation in experimental sepsis. J Surg Res 2016; 200: 266–273.
45.
Ang MTC, Gumbau-Brisa R, Allan DS, McDonald R, Ferguson MJ, Holbein BE, et al: DIBI, a 3-hydroxypyridin-4-one chelator iron-binding polymer with enhanced antimicrobial activity. Medchemcomm 2018; 9: 1206–1212.
46.
Parquet MDC, Savage KA, Allan DS, Davidson RJ, Holbein BE: Novel iron-chelator DIBI inhibits Staphylococcus aureus growth, suppresses experimental MRSA infection in mice and enhances the activities of diverse antibiotics in vitro. Front Microbiol 2018; 9: 1811.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.